Alector Inc(ALEC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.09 | Insider Own | 26.52% | Shs Outstand | 111.7M | Perf Week | 20.32% |
| Market Cap | 0.33B | Forward P/E | - | EPS next Y | -118.98% | Insider Trans | -0.57% | Shs Float | 108.9M | Perf Month | 20.32% |
| Enterprise Value | 0.19B | PEG | - | EPS next Q | -0.22 | Inst Own | 71.17% | Short Float | 9.41% | Perf Quarter | 38.89% |
| Income | -0.12B | P/S | 24.07 | EPS this Y | 72.53% | Inst Trans | 1.88% | Short Ratio | 3.17 | Perf Half Y | -2.17% |
| Sales | 0.01B | P/B | - | EPS next 5Y | 20.29% | ROA | -42.15% | Short Interest | 10.25M | Perf YTD | 44.23% |
| Book/sh | -0.09 | P/C | 1.93 | EPS past 3/5Y | 4.96% 10.72% | ROE | -385.11% | 52W High | -18.48% ($2.76) | Perf Year | 50% |
| Cash/sh | 1.17 | P/FCF | - | Sales past 3/5Y | -46% -0.05% | ROIC | -3160.47% | 52W Low | 106.42% ($1.09) | Perf 3Y | -56.14% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 6.27% | Gross Margin | 37.07% | Volatility(W/M) | 10.02% 11.87% | Perf 5Y | -89.84% |
| Dividend TTM | - | EV/Sales | 13.96 | Sales Y/Y TTM | -82.91% | Oper. Margin | -856.86% | ATR (14) | 0.2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.26 | EPS Q/Q | 32.03% | Profit Margin | -850.13% | RSI (14) | 62.72 | Recom | 2.57 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.26 | Sales Q/Q | -57.84% | SMA20 | 16.28% ($1.93) | Beta | 0.65 | Target Price | $3.9 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | 7.79% ($2.09) | Rel Volume | 0.59 | Prev Close | $2.1 |
| Employees | 103 | LT Debt/Eq | - | EPS/Sales Surpr. | 8.14% 93.78% | SMA200 | 10.96% ($2.03) | Avg Volume(3M) | 3.24M | Price | $2.25 |
| IPO | 2019/2/7 | Option/Short | Yes/Yes | Trades | 7465 | Volume | 1,910,285 | Change | 7.14% |
🧬 Alector is a US clinical-stage biotech company focused on immuno-neurology. It targets neurodegenerative diseases such as frontotemporal dementia and Alzheimer's, developing a pipeline of genetically validated antibody, enzyme, and siRNA candidates. The company is primarily a drug developer advancing its lead programs through a collaboration with global pharmaceutical company GSK.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
Traded less than usual. That is 59% of its average volume.
ALEC has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +72.5% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,407. Peers typically go for $1,089.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -89.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 71.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #258 of 594 in the industry
Based on market cap of $334M.
FAQ
What kind of company is ALEC?
ALEC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ALEC?
The market cap of ALEC is approximately $334M, ranking 3,536 within its sector.
What is the 52-week high and low for ALEC?
ALEC has recorded a 52-week high of $2.76 and a low of $1.09.
